Adding, as there is a new ANDA approval from the USFDA.
Ketorolac Tromethamine Injection – 15 mg/mL and 30 mg/mL Single-dose Vial.
US sales per year – 53 million USD (as per the disclosure by caplin)
Other active Indian competitors for this injection : Alembic, Gland, Sun pharma, Wockhardt
Caplin was already producing Ketorolac from 2017-18. They were selling it to Baxter Healthcare.
I think now they can independently sell on their own with better margins. This injection has good competition, but the opportunity size also looks relatively large.
Alembic management comments on Ketorolac opportunity (Ref Q2 FY23 concall)
Disc: Invested, No transaction in last 30 days.
| Subscribe To Our Free Newsletter |
